Analysis: FDA’s COVID-19 Accelerated Pathways

\n\nAt the October 2021 DIA conference on Digital Technologies in Clinical Trials, Pfizer reported the following timeline for the Pfizer-BioNTech COVID-19 vaccine\nclinical program:\n\nOn May 4, 2020, the Phase I study was initiated, followed by initiation of the Phase II/III program on July 27, 2020. Positive interim results were reported on November 18, 2020 followed by the Emergency Use Authorization (EUA) submission request on November 20, 2020.

Read the source article at Applied Clinical Trials Online
2021-12-07 18:46:00